Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial (vol 12, 104, 2023)

被引：0
|
作者：
Zakaraia, Haitham G. [1 ]
Salem, Heba F. [2 ]
Mostafa, Mostafa A. A. [3 ]
Ali, Ahmed M. [4 ]
Rabea, Hoda M. [5 ]
机构：
[1] Univ Sadat City, Fac Pharm, Clin Pharm Dept, POB 32897, Sadat City, Menoufia, Egypt
[2] Beni Suef Univ, Fac Pharm, Pharmaceut & Ind Pharm Dept, POB 62514, Bani Suwayf, Egypt
[3] October 6 Univ, Fac Med, Internal Med Dept, POB 12585, Giza, Egypt
[4] October 6 Univ, Fac Pharm, Clin Pharm Dept, POB 12585, Giza, Egypt
[5] Beni Suef Univ, Fac Pharm, Clin Pharm Dept, POB 62514, Bani Suwayf, Egypt
来源：
BENI-SUEF UNIVERSITY JOURNAL OF BASIC AND APPLIED SCIENCES | 2024年 / 13卷 / 01期
关键词：
D O I：
10.1186/s43088-024-00487-9
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Retagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial
    Guo, Lixin
    Tian, Fengsheng
    Liu, Li
    Chen, Mingwei
    Jiang, Chengxia
    Li, Shuangqing
    Liu, Cong
    Zhang, Yawei
    Qin, Jie
    Yu, Dongni
    Zong, Yicen
    Dai, Wei
    DIABETES OBESITY & METABOLISM, 2024, 26 (07): : 2830 - 2838
  • [42] Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
    Kovacs, C. S.
    Seshiah, V.
    Swallow, R.
    Jones, R.
    Rattunde, H.
    Woerle, H. J.
    Broedl, U. C.
    DIABETES OBESITY & METABOLISM, 2014, 16 (02): : 147 - 158
  • [43] Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension
    Hong, Sang-Mo
    Park, Cheol-Young
    Hwang, Dong-Min
    Han, Kyung Ah
    Lee, Chang Beom
    Chung, Choon Hee
    Yoon, Kun-Ho
    Mok, Ji-Oh
    Park, Kyong Soo
    Park, Sung-Woo
    DIABETES OBESITY & METABOLISM, 2017, 19 (05): : 654 - 663
  • [44] Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study
    Hirose, Takahisa
    Suzuki, Manabu
    Tsumiyama, Isao
    DIABETES THERAPY, 2015, 6 (04) : 559 - 571
  • [45] A 52-week extension study of switching from gemigliptin vs sitagliptin to gemigliptin only as add-on therapy for patients with type 2 diabetes who are inadequately controlled with metformin alone
    Jung, Chan-Hee
    Rhee, Eun-Jung
    Lee, Won-Young
    Min, Kyung Wan
    Shivane, Vyankatesh K.
    Sosale, Aravind R.
    Jang, Hak Chul
    Chung, Choon Hee
    Nam-Goong, Il Seong
    DIABETES OBESITY & METABOLISM, 2018, 20 (06): : 1535 - 1541
  • [46] Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study
    Takahisa Hirose
    Manabu Suzuki
    Isao Tsumiyama
    Diabetes Therapy, 2015, 6 : 559 - 571
  • [47] Exenatide Add-on to Continuous Subcutaneous Insulin Infusion Therapy Reduces Bolus Insulin Doses in Patients with Type 2 Diabetes: A Randomized, Controlled, Open-Label Trial
    Feng-fei Li
    Lanlan Jiang
    Liyuan Fu
    Hong-hong Zhu
    Peihua Zhou
    Danfeng Zhang
    Xiao-fei Su
    Jin-dan Wu
    Lei Ye
    Jian-hua Ma
    Diabetes Therapy, 2017, 8 : 177 - 187
  • [48] Exenatide Add-on to Continuous Subcutaneous Insulin Infusion Therapy Reduces Bolus Insulin Doses in Patients with Type 2 Diabetes: A Randomized, Controlled, Open-Label Trial
    Li, Feng-fei
    Jiang, Lanlan
    Fu, Liyuan
    Zhu, Hong-hong
    Zhou, Peihua
    Zhang, Danfeng
    Su, Xiao-fei
    Wu, Jin-dan
    Ye, Lei
    Ma, Jian-hua
    DIABETES THERAPY, 2017, 8 (01) : 177 - 187
  • [49] Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial
    Tanaka, Masashi
    Yamakage, Hajime
    Inoue, Takayuki
    Odori, Shinji
    Kusakabe, Toru
    Shimatsu, Akira
    Satoh-Asahara, Noriko
    INTERNAL MEDICINE, 2020, 59 (05) : 601 - 609
  • [50] Efficacy and safety of evogliptin versus sitagliptin as an add-on therapy in Indian patients with type 2 diabetes mellitus inadequately controlled with metformin: A 24-week randomized, double-blind, non-inferiority, EVOLUTION INDIA study
    Ajmani, Ajay Kumar
    Agrawal, Aparna
    Prasad, B. L. N.
    Basu, Indraneel
    Shembalkar, Jayashree
    Manikanth, Neeraj
    Subrahmanyam, K. A. V.
    Srinivasa, M.
    Chawla, Manoj
    Srivastava, Manoj Kumar
    Jebasingh, Felix
    Achappa, Basavaprabhu
    Agrawal, R. P.
    Pulichikkat, Rakesh K.
    Meena, Ramdhan
    Bhatia, Shailaja
    Gupta, Sandeep Kumar
    Dange, Amol
    Srivastava, Ambrish
    Trailokya, Abhijit
    Shahavi, Vinayaka
    Shende, Sachin
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 157
12345